tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Ventricular Dysfunction, Left D018487 33 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Oral Ulcer D019226 1 associated lipids
Endotoxemia D019446 27 associated lipids
Pouchitis D019449 3 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
O'Grady J C(2) monitoring: out of the blocks but with some way to go! 2004 Transplantation pmid:15201659
Tydén G et al. Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations. 2007 Transplantation pmid:17496528
Silva HT et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. 2014 Transplantation pmid:24521771
Heffron TG et al. Pediatric liver transplantation with daclizumab induction. 2003 Transplantation pmid:12829908
Peloso LJ et al. The serum concentration of tacrolimus after ingesting omeprazole: a pilot study. 2014 Transplantation pmid:25221905
Alhamad T et al. Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy. 2017 Transplantation pmid:28422926
Robertsen I et al. Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. 2015 Transplantation pmid:25148382
Lenaers JI et al. Relevance of posttransplant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients. 2006 Transplantation pmid:17102764
Nashan B et al. Clinical validation studies of Neoral C(2) monitoring: a review. 2002 Transplantation pmid:12023607
Camirand G et al. Combined immunosuppression of mycophenolate mofetil and FK506 for myoblast transplantation in mdx mice. 2001 Transplantation pmid:11468532
Gallon L et al. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. 2006 Transplantation pmid:16477235
Chan K et al. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial. 2011 Transplantation pmid:21836540
Herzog D et al. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. 2006 Transplantation pmid:16534467
Taler SJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. 1996 Transplantation pmid:8970613
Srinivas TR et al. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. 2005 Transplantation pmid:16251854
Blakolmer K et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. 2000 Transplantation pmid:10868635
Miller J et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. 2000 Transplantation pmid:10755543
Dieterle CD et al. Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. 2004 Transplantation pmid:15239622
MacPhee IA and Holt DW A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. 2008 Transplantation pmid:18212618
Oku M et al. Hepatocyte growth factor sustains T regulatory cells and prolongs the survival of kidney allografts in major histocompatibility complex-inbred CLAWN-miniature swine. 2012 Transplantation pmid:22158517